Share on StockTwits

Pacira Pharmaceuticals (NASDAQ:PCRX) Director Andreas Wicki sold 21,494 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $108.11, for a total value of $2,323,716.34. The sale was disclosed in a document filed with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Pacira Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $104.68.

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 108.25 on Wednesday. Pacira Pharmaceuticals has a 52-week low of $36.38 and a 52-week high of $109.94. The stock has a 50-day moving average of $96.95 and a 200-day moving average of $81.49. The company’s market cap is $3.885 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, July 31st. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. Pacira Pharmaceuticals’s revenue was up 175.2% compared to the same quarter last year. On average, analysts predict that Pacira Pharmaceuticals will post $0.23 earnings per share for the current fiscal year.

Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.

Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.